Post by icemandios on Oct 6, 2023 13:05:09 GMT
Rule 17(e) Announcement - Horizon Therapeutics plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
FOR IMMEDIATE RELEASE
October 6, 2023
RECOMMENDED CASH OFFER
for
HORIZON THERAPEUTICS PLC
by
Pillartree Limited, a private limited company wholly owned by Amgen Inc.
to be implemented by way of a scheme of arrangement
under Chapter 1 of Part 9 of the Irish Companies Act 2014
Announcement relating to the Scheme becoming effective
Horizon Therapeutics plc, a public limited company incorporated in Ireland (" Horizon " or the " Company ") announces that the Irish High Court-sanctioned scheme of arrangement between Horizon and its shareholders under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the " Scheme ") pursuant to which Pillartree Limited, a private limited company wholly owned by Amgen Inc., a Delaware corporation (" Amgen "), would acquire the entire issued ordinary share capital of Horizon (the " Acquisition "), became effective today, October 6, 2023.
Payment of the Scheme Consideration to the Scheme Shareholders pursuant to the Scheme is being commenced by Amgen today, October 6, 2023.
Trading of Horizon Shares on the Nasdaq Global Select Market (" Nasdaq ") was halted with effect from 8:00 p.m. (E.T.) on October 5, 2023, will remain halted on October 6, and will be suspended effective October 9, 2023.
Certain capitalised words used in this announcement and not herein defined have the meanings given to such words in the Scheme set forth in Part 3 of the proxy statement filed by the Company with the United States Securities and Exchange Commission (the " SEC ") on January 23, 2023.
Statement Required by the Irish Takeover Rules
The directors of Horizon accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors of Horizon (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
FOR IMMEDIATE RELEASE
October 6, 2023
RECOMMENDED CASH OFFER
for
HORIZON THERAPEUTICS PLC
by
Pillartree Limited, a private limited company wholly owned by Amgen Inc.
to be implemented by way of a scheme of arrangement
under Chapter 1 of Part 9 of the Irish Companies Act 2014
Announcement relating to the Scheme becoming effective
Horizon Therapeutics plc, a public limited company incorporated in Ireland (" Horizon " or the " Company ") announces that the Irish High Court-sanctioned scheme of arrangement between Horizon and its shareholders under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the " Scheme ") pursuant to which Pillartree Limited, a private limited company wholly owned by Amgen Inc., a Delaware corporation (" Amgen "), would acquire the entire issued ordinary share capital of Horizon (the " Acquisition "), became effective today, October 6, 2023.
Payment of the Scheme Consideration to the Scheme Shareholders pursuant to the Scheme is being commenced by Amgen today, October 6, 2023.
Trading of Horizon Shares on the Nasdaq Global Select Market (" Nasdaq ") was halted with effect from 8:00 p.m. (E.T.) on October 5, 2023, will remain halted on October 6, and will be suspended effective October 9, 2023.
Certain capitalised words used in this announcement and not herein defined have the meanings given to such words in the Scheme set forth in Part 3 of the proxy statement filed by the Company with the United States Securities and Exchange Commission (the " SEC ") on January 23, 2023.
Statement Required by the Irish Takeover Rules
The directors of Horizon accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors of Horizon (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.